JP2007502864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502864A5 JP2007502864A5 JP2006533279A JP2006533279A JP2007502864A5 JP 2007502864 A5 JP2007502864 A5 JP 2007502864A5 JP 2006533279 A JP2006533279 A JP 2006533279A JP 2006533279 A JP2006533279 A JP 2006533279A JP 2007502864 A5 JP2007502864 A5 JP 2007502864A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- alkyl
- alkenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44617003A | 2003-05-23 | 2003-05-23 | |
| US10/457,034 US7354932B2 (en) | 2001-12-21 | 2003-06-06 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| PCT/US2004/015977 WO2004106493A2 (en) | 2003-05-23 | 2004-05-21 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502864A JP2007502864A (ja) | 2007-02-15 |
| JP2007502864A5 true JP2007502864A5 (https=) | 2007-07-19 |
Family
ID=33493026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533279A Pending JP2007502864A (ja) | 2003-05-23 | 2004-05-21 | 有効性を高めたケモカインレセプタ結合複素環化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US7354932B2 (https=) |
| EP (1) | EP1628533A4 (https=) |
| JP (1) | JP2007502864A (https=) |
| CA (1) | CA2522535C (https=) |
| WO (1) | WO2004106493A2 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US20220409589A1 (en) * | 2001-12-21 | 2022-12-29 | Genzyme Corporation | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7498323B2 (en) * | 2003-04-18 | 2009-03-03 | Ono Pharmaceuticals Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
| CN1930127B (zh) * | 2004-03-15 | 2012-11-21 | 阿诺麦德股份有限公司 | 用于合成cxcr4拮抗剂的方法 |
| DE102004023506A1 (de) | 2004-05-10 | 2005-12-01 | Grünenthal GmbH | Kettenverlängerte substituierte Cyclohexyl-1,4-diamin-Derivate |
| WO2006022454A1 (ja) * | 2004-08-27 | 2006-03-02 | Ono Pharmaceutical Co., Ltd | 塩基性基を含有する化合物およびその用途 |
| TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
| UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
| AU2006203826A1 (en) | 2005-01-07 | 2006-07-13 | Emory University | CXCR4 antagonists for the treatment of HIV infection |
| US20090093454A1 (en) * | 2005-03-04 | 2009-04-09 | Kristjan Gudmundsson | Chemical Compounds |
| US20080214562A1 (en) * | 2005-07-11 | 2008-09-04 | Kristjan Gudmundsson | Chemical Compounds |
| WO2007058322A1 (ja) * | 2005-11-18 | 2007-05-24 | Ono Pharmaceutical Co., Ltd. | 塩基性基を含有する化合物およびその用途 |
| EP2397148A3 (en) | 2006-02-02 | 2012-04-25 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| EP2042503B1 (en) * | 2006-05-16 | 2013-01-30 | Ono Pharmaceutical Co., Ltd. | Compound having acidic group which may be protected, and use thereof |
| EP2041067A4 (en) | 2006-07-11 | 2009-11-25 | Univ Emory | CXER4 ANTAGONISTS WITH DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL PROBLEMS |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| AU2009228034A1 (en) | 2008-03-28 | 2009-10-01 | Altiris Therapeutics | Chemokine receptor modulators |
| WO2010099600A1 (en) * | 2009-03-02 | 2010-09-10 | Tucker William G | Compounds and methods for treating cancer and viral infections |
| CN103313989B (zh) | 2010-12-16 | 2016-05-04 | 霍夫曼-拉罗奇有限公司 | 三环pi3k抑制剂化合物和使用方法 |
| CA2825028A1 (en) * | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
| CN109069426B (zh) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| PL3393468T3 (pl) | 2015-12-22 | 2023-01-23 | X4 Pharmaceuticals, Inc. | Metody leczenia niedoboru odporności |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| WO2019126106A1 (en) * | 2017-12-19 | 2019-06-27 | X4 Pharmaceuticals, Inc. | Acyclic cxcr4 inhibitors and uses thereof |
| US11949239B2 (en) | 2018-07-05 | 2024-04-02 | Hitachi Energy Switzerland Ag | Technologies for solar power system performance model tuning |
| US10548889B1 (en) * | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020117782A1 (en) * | 2018-12-03 | 2020-06-11 | The University Of North Carolina At Chapel Hill | Methods for attenuating graft-versus-host disease and opportunistic infections |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| CN100525766C (zh) | 1997-06-02 | 2009-08-12 | 詹森药业有限公司 | 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物 |
| WO1999004794A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| EP1031563B1 (en) | 1997-09-30 | 2005-12-28 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| BR0010655A (pt) | 1999-03-24 | 2002-02-13 | Anormed Inc | Compostos heterocìclicos para ligação ao receptor de quimiocina |
| US6683192B2 (en) * | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| CA2419224A1 (en) | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| US6835731B2 (en) | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| PT1317451E (pt) | 2000-09-15 | 2006-12-29 | Anormed Inc | Compostos heterocíclicos que se ligam a receptores de quimioquinas |
| MXPA03005152A (es) | 2000-12-11 | 2004-10-14 | Tularik Inc | Antogonista de cxcr3. |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| ES2380009T3 (es) | 2001-07-31 | 2012-05-07 | Genzyme Global S.A.R.L. | Métodos para movilizar las células madre/progenitoras |
| US8178123B2 (en) * | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| WO2003022785A2 (en) | 2001-09-12 | 2003-03-20 | Anormed Inc. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| CA2467718C (en) * | 2001-12-21 | 2011-04-26 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| EP1613613B1 (en) | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| CN1930127B (zh) | 2004-03-15 | 2012-11-21 | 阿诺麦德股份有限公司 | 用于合成cxcr4拮抗剂的方法 |
| TW200619206A (en) * | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
-
2003
- 2003-06-06 US US10/457,034 patent/US7354932B2/en not_active Expired - Lifetime
-
2004
- 2004-05-21 WO PCT/US2004/015977 patent/WO2004106493A2/en not_active Ceased
- 2004-05-21 JP JP2006533279A patent/JP2007502864A/ja active Pending
- 2004-05-21 CA CA2522535A patent/CA2522535C/en not_active Expired - Lifetime
- 2004-05-21 EP EP04752905A patent/EP1628533A4/en not_active Withdrawn
-
2008
- 2008-02-22 US US12/036,187 patent/US20080167341A1/en not_active Abandoned
-
2012
- 2012-01-25 US US13/358,041 patent/US8778967B2/en not_active Expired - Lifetime
-
2014
- 2014-06-12 US US14/302,828 patent/US20150038509A1/en not_active Abandoned
-
2016
- 2016-02-08 US US15/018,698 patent/US10322111B2/en not_active Expired - Lifetime
-
2019
- 2019-04-10 US US16/380,365 patent/US20200000774A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502864A5 (https=) | ||
| US20230233579A1 (en) | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids | |
| CA2522535A1 (en) | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | |
| RU2004105961A (ru) | Способы активации клеток-предшественников/стволовых клеток | |
| Guinan et al. | Intravascular hemolysis and renal insufficiency after bone marrow transplantation | |
| JP2006526646A5 (https=) | ||
| Hesse et al. | Layered double hydroxides as efficient drug delivery system of ciprofloxacin in the middle ear: an animal study in rabbits | |
| Loftus et al. | The postinjury inflammatory state and the bone marrow response to anemia | |
| JP2013231086A (ja) | 化学療法の強化方法 | |
| KR20100017763A (ko) | 상승 효과가 있는 암 치료용 약제 조합물 | |
| Couban et al. | Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients | |
| JP2012522841A5 (https=) | ||
| KR20130142164A (ko) | 암 치료 및 면역억제를 위한 시로신고핀과 미토콘드리아 억제제의 조합물 | |
| JP2005532373A5 (https=) | ||
| JP5457196B2 (ja) | Ｃｎｄａｃ（２’−シアノ−２’−デオキシ−ｎ４−パルミトイル−１−ベータ−ｄ−アラビノフラノシル−シトシン）及び細胞毒性薬を含む組合せ | |
| JP5818905B2 (ja) | エリスロポエチン産生促進剤 | |
| Maron-Gutierrez et al. | Insult-dependent effect of bone marrow cell therapy on inflammatory response in a murine model of extrapulmonary acute respiratory distress syndrome | |
| Russo et al. | Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells | |
| TWI245643B (en) | Composition for selective cancer chemotherapy | |
| RU2008151054A (ru) | Применение ингибиторов рецептора эндотелиального фактора роста сосудов для лечения рака | |
| PT2754441E (pt) | Composição para a prevenção e tratamento de cancro do pulmão de não pequenas células, contendo derivados de pirazino-triazina | |
| Fowler et al. | Targeting the canonical nuclear factor-κB pathway with a high-potency IKK2 inhibitor improves outcomes in a mouse model of idiopathic pneumonia syndrome | |
| WO2022200926A1 (en) | Use of the sesquiterpene lactone tomentosin in the treatment of tumors caused by lymphoid cell lines | |
| CN113694205A (zh) | 5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用 | |
| Naik et al. | Role of colony stimulating factor 1 (CSF-1) and its receptor CSF1R: macrophage repolarization for glioblastoma treatment |